225 related articles for article (PubMed ID: 15355921)
1. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
de Jong FA; Marsh S; Mathijssen RH; King C; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2004 Sep; 10(17):5889-94. PubMed ID: 15355921
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
Zhou Q; Sparreboom A; Tan EH; Cheung YB; Lee A; Poon D; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2005 Apr; 59(4):415-24. PubMed ID: 15801936
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
[TBL] [Abstract][Full Text] [Related]
4. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Jada SR; Lim R; Wong CI; Shu X; Lee SC; Zhou Q; Goh BC; Chowbay B
Cancer Sci; 2007 Sep; 98(9):1461-7. PubMed ID: 17627617
[TBL] [Abstract][Full Text] [Related]
5. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
6. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
Kim KA; Joo HJ; Park JY
J Clin Pharm Ther; 2010 Dec; 35(6):705-12. PubMed ID: 21054463
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of irinotecan metabolism and transport: an update.
Smith NF; Figg WD; Sparreboom A
Toxicol In Vitro; 2006 Mar; 20(2):163-75. PubMed ID: 16271446
[TBL] [Abstract][Full Text] [Related]
8. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Arnaud O; Boumendjel A; Gèze A; Honorat M; Matera EL; Guitton J; Stein WD; Bates SE; Falson P; Dumontet C; Di Pietro A; Payen L
Eur J Cancer; 2011 Mar; 47(4):640-8. PubMed ID: 21216589
[TBL] [Abstract][Full Text] [Related]
9. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
[TBL] [Abstract][Full Text] [Related]
10. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Sparreboom A; Gelderblom H; Marsh S; Ahluwalia R; Obach R; Principe P; Twelves C; Verweij J; McLeod HL
Clin Pharmacol Ther; 2004 Jul; 76(1):38-44. PubMed ID: 15229462
[TBL] [Abstract][Full Text] [Related]
11. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
[TBL] [Abstract][Full Text] [Related]
12. Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions.
Sakiyama M; Matsuo H; Takada Y; Nakamura T; Nakayama A; Takada T; Kitajiri S; Wakai K; Suzuki H; Shinomiya N
Drug Metab Pharmacokinet; 2014; 29(6):490-2. PubMed ID: 24869748
[TBL] [Abstract][Full Text] [Related]
13. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W
Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217
[TBL] [Abstract][Full Text] [Related]
14. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.
Lal S; Wong ZW; Sandanaraj E; Xiang X; Ang PC; Lee EJ; Chowbay B
Cancer Sci; 2008 Apr; 99(4):816-23. PubMed ID: 18377430
[TBL] [Abstract][Full Text] [Related]
15. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
16. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.
Bessho Y; Oguri T; Achiwa H; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
Cancer Sci; 2006 Mar; 97(3):192-8. PubMed ID: 16542215
[TBL] [Abstract][Full Text] [Related]
17. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.
Maekawa K; Itoda M; Sai K; Saito Y; Kaniwa N; Shirao K; Hamaguchi T; Kunitoh H; Yamamoto N; Tamura T; Minami H; Kubota K; Ohtsu A; Yoshida T; Saijo N; Kamatani N; Ozawa S; Sawada J
Drug Metab Pharmacokinet; 2006 Apr; 21(2):109-21. PubMed ID: 16702730
[TBL] [Abstract][Full Text] [Related]
19. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
[TBL] [Abstract][Full Text] [Related]
20. Associations between ABCG2 gene polymorphisms and isolated septal defects in a Han Chinese population.
Wang C; Xie L; Li H; Li Y; Mu D; Zhou R; Liu R; Zhou K; Hua Y
DNA Cell Biol; 2014 Oct; 33(10):689-98. PubMed ID: 24979295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]